Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial

Multidrug Resistant Tuberculosis Clinical Trial

— PRACTECAL-PRO  

Official title:

Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03942354
• Other study ID #: PRACTECAL-PRO
• Status: Completed
• Start date: September 1, 2019
• Est. completion date: May 10, 2022

Study information

• Verified date: May 2024
• Source: Medecins Sans Frontieres, Netherlands
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

PRACTECAL-PRO is a sub-study of a TB-PRACTECAL clinical trial for multidrug resistant Tuberculosis. It evaluates the effectiveness of TB-PRACTECAL interventions from the patient perspective in terms of their quality of life, shared decision making and satisfaction with services.

Description:

Tolerability of drugs for TB is a complex and dynamic course for patients with drug resistance and can be affected by many different factors. A deeper understanding of the perspectives and experience of men and women participating in novel TB treatment trials will add to the understanding of the safety and efficacy of treatment.

TB-PRACTECAL is a multicentre, open label, phase 2-3 randomised controlled trial evaluating exclusively oral 6 months regimens containing bedaquiline, pretomanid, linezolid +/- moxifloxacin or clofazimine for the treatment of microbiologically confirmed pulmonary M/XDR-TB. It is registered with the ClinicalTrials.gov with identifier number NCT02589782. The trial aims to recruit 630 adults from two sites in Uzbekistan (Nukus and Tashkent) and one site each from Belarus and South Africa.

The TB-PRACTECAL trial assumes that even if the investigational arms would have non-inferior efficacy and safety compared to the standard of care outcomes, patients would prefer a shorter, exclusively oral regimen with a lower pill count. This study therefore aims to describe patient experiences (i.e. the quality of the treatment experience as opposed to the quantity of treatment or the amount of time spent on it).

The PRACTECAL-PRO sub-study aims to answer the question: "What are the perceptions, expectations and experiences of novel TB treatment for adult patients participating in a six-month regimen clinical trial in Uzbekistan, South Africa and Belarus?"

The objectives for the analysis are:

• To compare baseline scores between trial patients (all interventional arm patients plus standard of care patients) with healthy controls.

• To assess changes in scores over time in patients on the intervention arms and patients on the standard of care arm.

• To assess the utility of the SF 12 and SGRQ in a TB clinical trial.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 137
• Est. completion date: May 10, 2022
• Est. primary completion date: May 10, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients recruited into the TB-PRACTECAL trial in the approved sites OR

• Local healthy-controls of a similar profile in terms of age and gender aged =18 years AND

• Literate in the study questionnaire languages

• Able to sign the sub-study informed consent form after agreeing to the additional interviews and completion of questionnaires.

Exclusion Criteria:

• TB patients excluded from TB-PRACTECAL clinical trial

• Healthy volenteers with co-morbidities

• Healthy volenteers found to have TB

Related Conditions & MeSH terms

• Multidrug Resistant Tuberculosis
• Tuberculosis
• Tuberculosis, Multidrug-Resistant

Intervention

Drug:
• Bedaquiline
Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
• Pretomanid
Pretomanid is a nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.
• Moxifloxacin
Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria
• Linezolid
Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.
• Clofazimine
Clofazimine is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.
• Directly observed therapy (DOT)
Standard therapy

Locations

Country	Name	City	State
Belarus	Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital	Minsk
South Africa	THINK Clinical Trial Unit, Hillcrest	Durban	KwaZulu-Natal
South Africa	Helen Jospeh Hospital	Johannesburg
South Africa	Doris Goodwin Hospital	Pietermaritzburg	KwaZulu Natal
Uzbekistan	Republican TB Hospital No. 2	Nukus	Karakalpakstan
Uzbekistan	Sh Alimov Republican Specialised Scientific-Practical Medical Centre for Phthysiology and Pulmonology Hospital	Tashkent

Sponsors (7)

Lead Sponsor	Collaborator
Medecins Sans Frontieres, Netherlands	London School of Hygiene and Tropical Medicine, Ministry of Health, Republic of Uzbekistan, Ministry of Public Health, Republic of Belarus, THINK TB & HIV Investigative Network, University of Sussex, Wits Health Consortium (Pty) Ltd

Countries where clinical trial is conducted

Belarus,  South Africa,  Uzbekistan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in St George's respiratory questionnaire SGRQ survey questionnaire from baseline to 12 months	To assess the quality of life (QoL) of trial patients from baseline to 12 months: both those treated in the investigational arms and the standard of care arm. For the SGRQ, a change of 4 points is suggested to indicate a clinically significant change, although the questionnaire was developed with patients who had COPD rather than TB. In the sub-study with a relatively small sample we cannot be confident about whether a change of 4 points represents a similarly significant change, but we will be mindful to assess this possibility. Ultimate aim is to determine whether disease-specific patient quality of life scores improve in investigational arm patients from baseline to successful completion of treatment.	12 months
Primary	Changes in Short form 12 survey questionnaire (patient satisfaction and experience) from baseline to 12 months	Two summary scores are reported from the SF-12 - a mental component score (MCS-12) and a physical component score (PCS-12). The scores may be reported as Z-scores (difference compared to the population average, measured in standard deviations). Ultimate aim is to determine whether disease-specific patient satisfaction scores improve in investigational arm patients from baseline to successful completion of treatment.	12 months